Health · Pharma & Biotech · 6 hrs ago
FDA approves first disease-modifying treatment for Alexander disease
The FDA approved Zanvastro, the first treatment designed to modify Alexander disease, a rare, progressive condition affecting the brain and spinal cord.
The disease is linked to mutations in the GFAP gene, which can cause an abnormal buildup of a protein in brain support cells.
It can begin in childhood or adulthood and may affect movement, speech and swallowing; until now, care mainly focused on symptoms.
Zanvastro reduces production of the GFAP protein to target a process linked to the disease’s progression.
The drug is given by injection into the spinal canal by a health professional once every three months.
In an international study involving 54 patients, motor function was stable during follow-up among those treated, according to the University of Wisconsin-Madison.
The approval follows research that began more than 30 years ago after genetically modified mice developed protein deposits resembling those found in people with the disease.
The US Food and Drug Administration approved Zanvastro as the first disease-modifying treatment for Alexander disease.
The rare, progressive neurological condition affects the brain and spinal cord and is associated with abnormal buildup of the GFAP protein.
Zanvastro is designed to reduce production of GFAP and is administered by injection into the spinal canal once every three months.
The clinical development included an international study involving 54 patients at 13 centers.
Researchers at the University of Wisconsin-Madison and the University of Alabama at Birmingham began related mouse studies in the 1990s.
- Who
- The FDA approved Zanvastro, developed by Ionis Pharmaceuticals in collaboration with the University of Wisconsin-Madison.
- What
- It is the first approved disease-modifying treatment for Alexander disease.
- When
- The approval was reported on October 13, 2026.
- Where
- The FDA in the United States approved it. The clinical study involved 13 centers internationally.
- Why
- The treatment is intended to reduce production of GFAP, a protein that builds up abnormally in the nervous system of people with the disease.
This story does not have two clearly opposing sides.
Researchers at the University of Wisconsin-Madison and the University of Alabama at Birmingham modified mice to produce high levels of GFAP.
Researchers linked mutations in the GFAP gene to Alexander disease, identifying a potential treatment target.
Ionis Pharmaceuticals conducted an international study involving 54 patients at 13 centers.
The FDA approval of Zanvastro was reported.
- Treatment
- Zanvastro
- Target protein
- GFAP
- Clinical study
- 54 patients at 13 centers
- Administration
- Injection into the spinal canal once every three months
- Disease prevalence
- Less than 1 person per 1 million according to the University of Wisconsin-Madison
Related
Racura trial advances to next RC220 dose after initial safety review
1 hr ago
Brazil bans and recalls FarmaUSA tirzepatide batch after destruction order ignored
4 hrs ago · 2 sources
GLP-1 drug users report more nail and hair problems in study
8 hrs ago · 2 sources
BioNTech cancer treatment misses goal in late-stage head and neck cancer trial
9 hrs ago · 2 sources
